Satellos to Update BASECAMP Strategy on Call
Clinical-stage biotech Satellos Bioscience will host an investor call on its Phase 2 pediatric Duchenne study strategy.
Updated on Nov. 5, 2026 in Biotech
Satellos Bioscience Inc. will host a conference call and audio webcast at 8:00 a.m. ET on Friday, November 6, 2026, to update the clinical and regulatory strategy for its BASECAMP Phase 2 study. The study evaluates forazapadin in boys ages 7, 8 or 9 with Duchenne muscular dystrophy.
Why it matters
The update addresses the clinical and regulatory path for a potential disease-modifying treatment for Duchenne muscular dystrophy in young children. Investors and families following the program will receive the company's latest strategy directly from its leadership.
The call is scheduled for 8:00 a.m. ET on November 6, 2026, and the BASECAMP study targets boys aged 7, 8 or 9 with Duchenne muscular dystrophy. The specific clinical and regulatory details of the strategy update remain undisclosed until the call takes place.
The players
Satellos Bioscience Inc.
A clinical-stage biotechnology company listed on NASDAQ as MSLE and on the TSX as MSCL, developing forazapadin for muscle diseases.
Frank Gleeson
Chief Executive Officer of Satellos Bioscience, who will provide remarks on the company's strategy during the call.
Wildon Farwell, M.D.
Chief Medical Officer of Satellos Bioscience, who will address the clinical aspects of the BASECAMP study on the call.
The details
Satellos Bioscience, a clinical-stage biotechnology company listed on NASDAQ as MSLE and on the TSX as MSCL, will hold the call with remarks from CEO Frank Gleeson and Chief Medical Officer Wildon Farwell, M.D. A live webcast and slides will be posted in the Investors section of the company website, with a replay available afterward.
Timeline
November 5, 2026: Satellos announces the investor call and audio webcast.
November 6, 2026, 8:00 a.m. ET: Investor conference call and audio webcast held.
Big Picture
Forazapadin is being tested in pediatric Duchenne patients as a potential disease-modifying option, part of the broader push to move oral small-molecule candidates into young patient cohorts. The company also plans to pursue additional muscle diseases and injury conditions in future clinical development.
Families of boys with Duchenne muscular dystrophy and observers of the field can watch the live webcast and review accompanying slides on the company's Investors page. A replay will be posted after the presentation for those unable to attend live.
The takeaway
Clinical strategy updates from early-stage pediatric trials often shape how families and physicians weigh emerging options for rare neuromuscular disease. Following the November 6 call and its replay offers the most direct view of where the BASECAMP program is headed.
What happens next
Satellos will host an investor conference call and audio webcast at 8:00 a.m. ET on Friday, November 6, 2026, to update its BASECAMP clinical and regulatory strategy, with a replay available afterward.
Further reading
Explore more on Biotech developments shaping clinical research worldwide.
Source note: This article includes information reported by Belleville Intelligencer.
